Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Alex1726on May 24, 2023 6:56am
61 Views
Post# 35461389

RE:RE:Nintedanib

RE:RE:NintedanibTo my point view CZO must move ahead with clinicals trials to evaluate this new approach , it is a must. How many clinicals trials CZO will need to do to get the best deal with a major (1 a, 1b,2a?) , how much will these cliniclas trials will cost? Will CZO decide to conduct those clinicals trials under FDA assesment or only with Health Canada?

Gagnon has a lot of work to do , is he the man that has all the skills to manage this big project? How experienced he is with the FDA , how many big investors can he involved to finance this project? Would it be the time for him to leave his place to someone else? As shareholders are we certain he could maximise shareholders value if  PGX-YBG reach a phase 2b for instance?

CZO is defenetly to a turning point and the next main decisions needs to be the right ones.
<< Previous
Bullboard Posts
Next >>